Lupin Strengthens U.S. Portfolio With Diabetes Drug Launch

Indian pharmaceutical company Lupin Limited has expanded its presence in the U.S. healthcare market with the launch of a diabetes medication after receiving approval from the United States Food and Drug Administration.

The company introduced Dapagliflozin Tablets in 5 mg and 10 mg strengths, aimed at helping adults manage Type 2 diabetes.

The newly launched medicine is a generic version of Farxiga, a widely used treatment prescribed to improve blood sugar control in people living with Type 2 diabetes. Dapagliflozin belongs to a group of medicines known as SGLT2 inhibitors, which work by helping the kidneys remove excess sugar from the body through urine.

The launch follows FDA approval of Lupin’s abbreviated new drug application (ANDA), a regulatory process that allows generic drug manufacturers to bring equivalent alternatives to the market. Approval confirms that Lupin’s version matches the branded medicine in safety, quality, and effectiveness.

Also Read: How India Became the Pharmacy of the World in a Constrained Economy

The United States remains one of Lupin’s most important business markets. By adding this diabetes treatment to its portfolio, the company is strengthening its position in the U.S. pharmaceutical market, a therapy area that continues to see strong demand. Rising cases of diabetes worldwide have increased the need for affordable diabetes treatment options, creating opportunities for generic drugmakers.

Industry experts believe the move aligns with Lupin’s strategy of expanding its presence in high-demand healthcare segments, including cardiovascular care and chronic disease management. Generic medicines often play a key role in lowering treatment costs and improving patient access to medicines, particularly in large healthcare systems like the U.S.

Headquartered in Mumbai, Lupin operates in more than 100 countries and has built a strong reputation in both branded and generic pharmaceuticals. The company continues to focus on FDA-approved drugs, product development, and manufacturing expansion to support its global growth plans.

The latest launch highlights Lupin’s ongoing efforts to grow its U.S. business while addressing the increasing demand for diabetes care solutions.